Brokerages Set TG Therapeutics, Inc. (NASDAQ:TGTX) PT at $43.80

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $43.80.

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 price target on the stock in a research note on Thursday, July 10th.

Insiders Place Their Bets

In other news, Director Yann Echelard sold 10,000 shares of the stock in a transaction on Friday, June 13th. The stock was sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the sale, the director owned 228,816 shares in the company, valued at $8,452,463.04. This represents a 4.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 10.64% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Ameritas Advisory Services LLC bought a new stake in shares of TG Therapeutics during the 2nd quarter valued at $25,000. Vermillion Wealth Management Inc. bought a new position in TG Therapeutics during the fourth quarter worth $30,000. NBC Securities Inc. raised its stake in TG Therapeutics by 82,300.0% during the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 823 shares during the last quarter. Golden State Wealth Management LLC raised its stake in TG Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 433 shares during the last quarter. Finally, SVB Wealth LLC bought a new position in TG Therapeutics during the first quarter worth $37,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Stock Performance

TGTX traded down $0.32 during trading on Monday, hitting $28.40. 5,074,384 shares of the company traded hands, compared to its average volume of 2,138,539. The firm has a market cap of $4.51 billion, a P/E ratio of 76.76 and a beta of 1.95. The stock's fifty day moving average is $36.71 and its 200 day moving average is $36.10. The company has a quick ratio of 3.04, a current ratio of 4.02 and a debt-to-equity ratio of 1.03. TG Therapeutics has a one year low of $18.65 and a one year high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.15). TG Therapeutics had a net margin of 13.31% and a return on equity of 27.83%. The firm had revenue of $141.15 million for the quarter, compared to the consensus estimate of $147.76 million. During the same period last year, the company posted $0.04 earnings per share. The business's revenue was up 92.1% on a year-over-year basis. As a group, equities analysts predict that TG Therapeutics will post 0.08 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.